These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35513341)

  • 41. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
    Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
    Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease.
    Ohgushi M; Ogo N; Yanagihara T; Harada Y; Sumida K; Egashira A; Asoh T; Maeyama T; Yoshizawa S
    Intern Med; 2022 Feb; 61(4):585-589. PubMed ID: 34866097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.
    Saketkoo LA; Mittoo S; Huscher D; Khanna D; Dellaripa PF; Distler O; Flaherty KR; Frankel S; Oddis CV; Denton CP; Fischer A; Kowal-Bielecka OM; LeSage D; Merkel PA; Phillips K; Pittrow D; Swigris J; Antoniou K; Baughman RP; Castelino FV; Christmann RB; Christopher-Stine L; Collard HR; Cottin V; Danoff S; Highland KB; Hummers L; Shah AA; Kim DS; Lynch DA; Miller FW; Proudman SM; Richeldi L; Ryu JH; Sandorfi N; Sarver C; Wells AU; Strand V; Matteson EL; Brown KK; Seibold JR;
    Thorax; 2014 May; 69(5):428-36. PubMed ID: 24368713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union.
    Takizawa A; Kamita M; Kondoh Y; Bando M; Kuwana M; Inoue Y
    Curr Med Res Opin; 2021 Feb; 37(2):327-339. PubMed ID: 33287583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 and acute exacerbation of interstitial lung disease.
    Kondoh Y; Kataoka K; Ando M; Awaya Y; Ichikado K; Kataoka M; Komase Y; Mineshita M; Ohno Y; Okamoto H; Ooki T; Tasaka Y; Tomioka H; Suda T
    Respir Investig; 2021 Sep; 59(5):675-678. PubMed ID: 34272158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unclassifiable interstitial lung disease: from phenotyping to possible treatments.
    Guler SA; Ryerson CJ
    Curr Opin Pulm Med; 2018 Sep; 24(5):461-468. PubMed ID: 30004990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease.
    Nishiyama N; Masuo M; Nukui Y; Tateishi T; Kishino M; Tateishi U; Morota K; Ohbo K; Miyazaki Y
    Respir Investig; 2021 Jan; 59(1):90-98. PubMed ID: 32919933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.
    Holtze C; Flaherty K; Kreuter M; Luppi F; Moua T; Vancheri C; Scholand MB
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
    Fischer A; Distler J
    Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons.
    Jee AS; Sahhar J; Youssef P; Bleasel J; Adelstein S; Nguyen M; Corte TJ
    Pharmacol Ther; 2019 Oct; 202():40-52. PubMed ID: 31153954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease.
    Johnston J; Dorrian D; Linden D; Stanel SC; Rivera-Ortega P; Chaudhuri N
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in rheumatoid arthritis-associated interstitial lung disease.
    Juge PA; Crestani B; Dieudé P
    Curr Opin Pulm Med; 2020 Sep; 26(5):477-486. PubMed ID: 32701675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [When COVID-19 encounters interstitial lung disease: challenges and management].
    Ren YH; Wang SY; Liu M; Guo YM; Dai HP
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Aug; 43(8):633-638. PubMed ID: 32198915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.
    Wong AW; Fidler L; Marcoux V; Johannson KA; Assayag D; Fisher JH; Hambly N; Kolb M; Morisset J; Shapera S; Ryerson CJ
    Chest; 2020 Sep; 158(3):1069-1078. PubMed ID: 32333929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
    Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
    Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.